Federation Des Caisses Desjardins Du Quebec Verve Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.9 Billion
- Q3 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 1,700 shares of VERV stock, worth $9,401. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,700
Previous 1,700
-0.0%
Holding current value
$9,401
Previous $8,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
185Shares Held
73.3MCall Options Held
85KPut Options Held
215K-
Alphabet Inc. Mountain View, CA12.3MShares$68.3 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$36.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$27.4 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$23.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$22.1 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $331M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...